hERG Screening

  • Check with publisher
  • Published date: January 15, 2020
    • Shirley, New York, United States

Cardiotoxicity is one of the major safety concerns in drug discovery, which is the leading reason for development termination and market withdraw or restriction. Particularly, hERG ion channel inhibition or blockade is responsible for 25-40% of all preclinical lead compound discontinuance. Human ether-a-go-go (hERG), a potassium channel that is abundant in the cardiomyocytes, represents one pivotal component for IKr currents and cardiac repolarization. Drug-induced interference of hERG causes QT interval prolongation, which is associated with fatal ventricular tachyarrhythmia called Torsade de Pointes (TdP). Given the unacceptable adverse effects of hERG inhibition and the fact that many drug-like molecules exhibit hERG affinity, hERG assessment has become one priority requirement by regulatory agencies before IND submission. https://www.creative-biolabs.com/drug-discovery/therapeutics/herg-screening.htm .

Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Drug-Drug Interactions

    Drug-Drug Interactions

    Biomedical Sciences Shirley (New York) January 15, 2020 Check with publisher

    As there is increasing population taking multiple medications, adverse drug-drug interactions (DDI) has become a crucial issue. If a certain component of drug A changes the activity of enzymes or transporters involved in the metabolism of drug B, it ...

  • Cardiotoxicity


    Biomedical Sciences Shirley (New York) January 15, 2020 Check with publisher

    Drug-induced cardiotoxicity is the leading cause of both drug development failures and market withdraw or restriction. Compounds that exert cardiovascular toxicity, no matter acute or subtle effect, can lead to severe adverse consequences, such as ar...

  • UGT Investigation

    UGT Investigation

    Biomedical Sciences Shirley (New York) January 15, 2020 Check with publisher

    Drug-drug interaction (DDI) is a major concern when multiple drugs are co-administrated and interfere the metabolism of one another. In effort to minimize DDI liability, a comprehensive understanding of drug metabolism pathway and interference potenc...